Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 Inactivated Varicella-Zoster Vaccine (ZV IN ) trial
Eriksson, Jennifer, Hunger, Matthias, Bourhis, François, Thorén, Robyn, Popmihajlov, Zoran, Finelli, Lynn, Jiang, YilingLanguage:
english
Journal:
Expert Review of Pharmacoeconomics & Outcomes Research
DOI:
10.1080/14737167.2020.1693267
Date:
November, 2019
File:
PDF, 1022 KB
english, 2019